Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2009; 1(02): 077-081
DOI: 10.4103/0974-2727.59705
Original Article

Long-Term Effect of Different Classes of Highly Active Antiretroviral Therapy on Transaminases

Ebele J Ikekpeazu
Department of Medical Biochemistry, College of Medicine, University of Nigeria Enugu Campus (UNEC), Enugu State, Nigeria
,
Emeka E Neboh
Department of Chemical Pathology and Paediatrics, College of Medicine, Enugu State, University Teaching Hospital (ESUTH), Enugu State, Nigeria
,
Ignatius C Maduka
Department of Chemical Pathology, University of Nigeria Teaching Hospital (UNTH), PMB, 01129, Enugu, Nigeria
,
Odutola Odetunde
Department of Paediatrics, College of Medicine, Enugu State, University Teaching Hospital (ESUTH), Enugu State, Nigeria
,
Uche Ifejimalu
Department of Medical Laboratory Sciences, Ambrose Alli University (AAU), Ekpoma, Edo State, Nigeria
› Author Affiliations Source of Support: Nil
› Further Information
  PDF Download Permissions and Reprints

ABSTRACT

AIM: The current use of highly active antiretroviral therapy (HAART) for HIV/AIDS patients has increased the recognition of their hepatotoxic effects. The present study is aimed at evaluating the level of aspartate transaminase (AST) and alanine transaminase (ALT) in HIV patients on different classes of HAART, for various durations, which causes its toxicity

Materials and Methods: The AST and ALT levels were estimated in a total of 340 subjects, of which 290 were HIV positive subjects drawn from patients attending the HIV clinic in two Teaching Hospitals, in Nigeria. 240 of the HIV patients were divided into 3 equal groups of 80 each and placed on non-nucleoside reverse transcriptase inhibitors (NNRTI), nucleoside reverse transcriptase inhibitors (NRTI), and protease inhibitors (PI), respectively, and were monitored for different periods of time (3, 6, 12, and >12 months). 50 of the HIV patients, yet to be placed on anti-retroviral therapy and 50 apparently healthy HIV-negative subjects served as the positive and negative controls, respectively.

Results: A significant increase in enzyme levels was noted at three and six months in the NNRTI group, and at only three months in the NRTI and PI groups, when compared with the controls. However, increased ALT was observed at six months in those on PI. The increased ALT and AST levels noted in the NNRTI group were significant when compared to those on NRTI and PI over a three- and six-month duration.

Conclusion: Liver enzyme activities were generally raised in the first three months of HAART, and further in the NNRTI group, after which they progressively fell to the normal level, with time. The highest degree was observed with NNRTIbased HAART.

Keywords

Duration - effects - HIV-patients - highly active antiretroviral therapy - liver enzymes


Publication History

Article published online:
29 January 2020

© 2009.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • REFERENCES

  • 1 Mayne DP. Liver Enzymes. In: Clinical Chemistry in diagnosis and Treatment: 5 th edition: London: Edward Arnold Publishers; 1971. p. 283-4.
  • 2 Wood E, Hogg RS, Yip B, Harrigan PB. Effect of Medication adherence on survival of HIV patient who start HAART when CD4+ cell count 200-240 cells/L. Ann Intern Med 2003;139:816-21.
  • 3 Havlir DV, Currier JS. Complications of HIV infection and antiretroviral therapy. Top HIV Med 2003;11:86-91.
  • 4 Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003;5:36-43.
  • 5 Hammer SM, Kessler HA, Saag MS. Issues in combination antiretroviral therapy. J Acquir Immune Defic SynDr. 1994;7:S24-35.
  • 6 Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre. AIDS 2001;15:185-94.
  • 7 Monier P, Mc Known K, Bronze MS. Complication issues in highly active antiretroviral therapy in HIV patients. Clin Infect Dis 2001;31:1488-92.
  • 8 Hooshyar D, Napravnik S, Miller W, Eron J. Effect of hepatitis-C co-infection on discontinuation and modification of initial HAART in primary HIV care. AIDS 2006;20:575-83.
  • 9 Cheesbrough M. Clinical Chemistry Tests. In: Cheesebrough M. (ed). District Laboratory Practice in Tropical Coutries, Part 1. Low Price edition, United Kingdom: CambridgeUniversity Press; 2002;437-52
  • 10 Reitman S, Frankel S. Standard methods in Clinical Chemistry. Am J Clin Chem 1957;28:56-9.
  • 11 Tuli L, Gulati AK, Sundar S, Mohapatra TM. Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons. An experience of a tertiary care hospital in Varanasi India. BMC Gastroenterol 2008;8:36-41.
  • 12 Meldrum J. Nevirapine-based fixed dose combination ARVS. GMHC Treat Issues 2003;17:5-9.